The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Weight loss jabs, known as GLP-1 receptor agonists, work by reducing food cravings. In October, the MHRA told health ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

The new drug, amycretin, similar to the company's blockbuster weight-loss and diabetes drugs Wegovy ... The company tested the once-weekly injection on 125 people for up to 36 weeks with ...

There are precedents for a hybrid NHS-private model of healthcare. Ten years ago, a new drug treatment arrived that could ...

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

The NPA has also previously urged patients to avoid buying weight loss injections from unregulated online sellers, who may be selling fake drugs. The Medicines and Healthcare Regulatory Agency ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...